Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.7M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
39.1M
-
Shares change
-
+5.54M
-
Total reported value, excl. options
-
$798M
-
Value change
-
+$113M
-
Put/Call ratio
-
0
-
Number of buys
-
43
-
Number of sells
-
-16
-
Price
-
$20.41
Significant Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q2 2023
71 filings reported holding ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2023.
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.1M shares
of 59.7M outstanding shares and own 65.43% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (9M shares), 5AM Venture Management, LLC (5.8M shares), FMR LLC (4M shares), COMMODORE CAPITAL LP (2.35M shares), CITADEL ADVISORS LLC (2.3M shares), VR Adviser, LLC (2.23M shares), Fairmount Funds Management LLC (2.12M shares), RA CAPITAL MANAGEMENT, L.P. (2.12M shares), Cormorant Asset Management, LP (1.94M shares), and BlackRock Inc. (1.55M shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.